1d agoThe FlyBULLISH 58Product/PR
Archived explainer. For the current picture see today's FRNM page.
Why Is FREENOME INC (FRNM) Stock Down Today?
By the Top Tier Newswire AI Desk · October 13, 2026 at 12:02 AM ET · reviewed against 3 wire stories
FREENOME INC (FRNM) is down -16.22% in the latest session. Our newswire has captured 3 stories on FRNM across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Freenome Inc (FRNM) shares fell 16.22% to close at $13.22. The primary driver of the decline appears to be a reaction to new validation data for its next-generation colorectal cancer screening test, SimpleScreen CRC, which the company plans to present at the ACG 2026 conference.
What Happened
Freenome announced it will deliver a late-breaking oral presentation at the ACG 2026 conference featuring new validation data for its next-generation CRC screening test. The company stated that the updated version of SimpleScreen CRC shows significant performance improvements across all subtypes of advanced precancerous lesions. These lesions are critical to detect for potential colorectal cancer prevention. The presentation highlights an overall detection improvement for the test.
In the background, market participants have been monitoring unconfirmed analyst comments suggesting that Carelon Healthcare Services updated its clinical guideline reimbursements to include Freenome’s SimpleScreen. Additionally, Guggenheim initiated coverage on Freenome with a Buy rating and a price target of $21. The company also filed a prospectus related to the offer and sale of up to 75,188,742 shares of common stock by selling securityholders.
What The Data Shows
Freenome has a market capitalization of $1.7 billion and remains unprofitable, with a trailing twelve-month EPS of -8.84. The stock has a beta of 0.45 and trades within a 52-week range of $9.97 to $17.50. Recent trading activity indicates that the stock printed four fresh 52-week highs and 31 fresh 52-week lows on October 12, 2026. The current price of $13.22 sits in the middle of this wide range, reflecting the volatility seen in the recent tape.
What To Watch
Investors will monitor the upcoming late-breaking oral presentation at ACG 2026 for further details on the SimpleScreen CRC performance data. The market will also watch for any confirmed updates regarding clinical guideline reimbursements and the impact of the recent prospectus filing on share supply.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
FRNM by the numbers
Last: $13.22Session: -16.22%Coverage: 3 stories / 3 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $1.7B52w: $9.97 to $17.50
The headlines behind the move
1d agoGlobeNewswireBULLISH 63Product/PR
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of...
1d agoBusiness InsiderBULLISH 63Product/PR
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on FRNM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier FRNM move explainers: 2026-10-13 · 2026-10-12